April 4, 2020

Paget’s Disease Treatment Market will be Growing at a CAGR of 3.4% during the forecast period from 2019 to 2027

According to the latest report published by Credence Research, Inc., the global Paget’s disease treatment market is expected to grow at a CAGR of 3.4% from 2019 to 2027.

Market Insights

Paget’s disease is a rare condition in which the normal cycle of bone renewal and bone repair is disordered or abnormal. This abnormal bone is fragile, has multiple blood vessels, and is larger than the normal bone. However, in most cases it does not cause symptoms, some patients may experience bone pain, fractures, deformities and, in rare cases, malignant transformation into tumors. Paget’s disease is most prevalent in geriatric patients, with countries with the highest geriatric population having the highest prevalence rates, such as the United Kingdom, Spain, Italy, France, the United States, Australia and New Zealand.

Browse the full report at https://www.credenceresearch.com/report/pagets-disease-treatment-market

Paget’s disease, when it occurs around the joint, is usually given specifically to prevent the development of osteoarthritis. In addition, young patients with Paget disease and those with high levels of bone-specific alkaline phosphatase (BSAP) are often treated to prevent future complications. Bone deformities are the second most common event with a prevalence ranging from 12 percent to 36 percent. The femur and tibia are the most common bones affected, and the bones are particularly bent, which is usually anterolateral in the femur and anterior in the tibia.

Drug classes involved in the treatment of Paget’s disease include bisphosphonates, calcitonin analogs, analgesics, and supplements (calcium & vitamin D). In 2018, bisphosphonates are expected to dominate the market throughout the forecast period due to key factors such as first-line treatment for Paget’s disease, and to a successful slowdown in bone remodeling. Market experts believed that bisphosphonate therapy should be preferred with a view to normalizing bone regeneration in the expectation that this would reduce the progression of the disease and prevent complications from developing.

North America is identified as the largest market for treatment of Paget’s disease due to an increasing prevalence of Paget’s disease combined with an increasing geriatric population and a high level of awareness of rare orthopedic diseases and treatment. According to the National Organization for Rare Disorders (NORD), the prevalence of Paget’s disease in the United States is estimated at 1-2 percent of the general population. However, Europe is expected to dominate Paget’s disease treatment market during the forecast period from 2019 to 2027 due to increased awareness and prevalence of Paget’s disease.

Credence Research is providing Free Sample Get it here: https://www.credenceresearch.com/sample-request/59734

Market Competition Assessment:

The Paget’s disease treatment market is growing gradually and awareness related to the disease is growing significantly. However, the pipeline is dry and key companies operating in this market lacked in innovation and ground-breaking treatment. The companies present in the global Paget’s disease treatment market are Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Neopharma, Inc., Sanofi S.A., Allergan, Fresenius Kabi, Sun Pharmaceutical Industries, Ltd., and Mallinckrodt Pharmaceuticals among others.

Key Market Movements:

  • Increasing prevalence and awareness related to Paget’s disease treatment & diagnosis expected to assist the market growth
  • Incessant demand for development of target-specific treatment for Paget’s disease treatment
  • Being an orphan disease and complexities related to diagnosis and disease management initiative related to research & development activities is not present

Report Scope by Segments

By Type of Drug Class

  • Bisphosphonates
    • Zoledronic acid
    • Pamidronate Disodium
    • Etidronate
    • Tiludronate
    • Alendronate
    • Risedronate
  • Calcitonin Analogues (Salmon Calcitonin)
  • Analgesics
  • Calcium & Vitamin D Supplements

By Geography Segment

  • North America (U.S., Rest of North America)
  • Europe (U.K., Germany, France, Rest of Europe)
  • Asia Pacific (China, Japan, India, Rest of Asia Pacific)
  • Rest of the World (Middle East & Africa, Latin America)

Credence Research is providing Free Sample Get it here: https://www.credenceresearch.com/sample-request/59734

Leave a Reply

Your email address will not be published. Required fields are marked *